Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 in Subjects With Autosomal Dominant Polycystic Kidney Disease

NCT02616055 is registered in ClinicalTrials.gov with Kadmon Corporation, LLC as lead sponsor.

NCT NCT02616055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02616055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 in Subjects With Autosomal Dominant Polycystic Kidney Disease
Lead sponsor
Kadmon Corporation, LLC
Phase
Phase 2
Overall status
Terminated
Start date
December 25, 2015
Completion date
December 21, 2016
Enrollment
15 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

autosomal dominant polycystic kidney disease (adpkd)